Taken together, previous data and our observations might justify a separation of CD5-positive DLBCL out of the group of DLBCL, NOS, as a distinct clinico-pathological entity in need of R-CHOP treatment alternatives and, probably, CNS prophylaxis. Here, CD5 is linked to diffuse large B-cell lymphoma.